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Abstract
Background:   SPARC is a matricellular protein involved in cell-matrix interactions. From
expression patterns at the wound site and in vitro studies, SPARC has been implicated in the
control of wound healing. Here we examined the function of SPARC in cutaneous wound healing
using SPARC-null mice and dermal fibroblasts derived from them.
Results:  In large (25 mm) wounds, SPARC-null mice showed a significant delay in healing as
compared to wild-type mice (31 days versus 24 days). Granulation tissue formation and
extracellular matrix protein production were delayed in small 6 mm SPARC-null wounds initially
but were resolved by day 6. In in vitro wound-healing assays, while wild-type primary dermal
fibroblasts showed essentially complete wound closure at 11 hours, wound closure of SPARC-null
cells was incomplete even at 31 hours. Addition of purified SPARC restored the normal time
course of wound closure. Treatment of SPARC-null cells with mitomycin C to analyze cell
migration without cell proliferation showed that wound repair remained incomplete after 31 hours.
Cell proliferation as measured by 3H-thymidine incorporation and collagen gel contraction by
SPARC-null cells were not compromised.
Conclusions:  A significant delay in healing large excisional wounds and setback in granulation
tissue formation and extracellular matrix protein production in small wounds establish that SPARC
is required for granulation tissue formation during normal repair of skin wounds in mice. A defect
in wound closure in vitro indicates that SPARC regulates cell migration. We conclude that SPARC
plays a role in wound repair by promoting fibroblast migration and thus granulation tissue
formation.
Background
Wound healing involves reepithelialization, granulation
tissue formation and contraction (reviewed in refs.
[1,2]). Reepithelialization and granulation tissue forma-
tion in turn involve proliferation and migration of cells
from the wound edge to fill the wound site. In higher ver-
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tebrate adult animals, reepithelialization of a wound be-
gins within hours after injury while granulation tissue
begins to form approximately 4 days after injury. Besides
fibroblasts, granulation tissue consists of macrophages,
blood vessels, and extracellular matrix (ECM) produced
by fibroblasts. Once the wound is filled with granulation
tissue and covered with a neoepidermis, a portion of the
wound fibroblasts transforms into myofibroblasts,
which contract the wound to reduce and strengthen the
defect. Myofibroblasts are rich in F-actin bundles, which
establish cell-cell and cell-matrix linkages and thus gen-
erate the force for wound contraction.
SPARC (secreted protein acidic and rich in cysteine) is an
extracellular glycoprotein expressed in elevated levels in
actively proliferating cells and organs such as developing
embryos and adult tissues associated with remodeling
(bone and gut), wound healing, angiogenesis (reviewed
in refs. [3,4]), and tumorigenesis [5,6]. SPARC belongs
to a class of recently denoted matricellular proteins that
are involved in cell-ECM interactions. It binds to ECM
proteins and interacts with cells. SPARC has been postu-
lated to modulate cell shape [3,4] and cell adhesions
[4,7,8], to regulate cell proliferation [3,4] and migration
[9,10], and to influence matrix contraction [11]. In addi-
tion, SPARC is known to bind to certain growth factors
[12] and to modulate expression of ECM components
[13]. Many of these functions are requisite to wound re-
pair.
To further investigate the role of SPARC in wound heal-
ing, we used cells from our recently generated SPARC-
null mice [14]. As we reported previously SPARC plays a
role in regulating expression of growth factors, growth
factor receptors, and ECM proteins and in modulating
cell proliferation. In the absence of SPARC, expression of
transforming growth factor-β 1 and type I collagen is
down-regulated in kidney mesangial cells [15]. The ex-
pression of cell surface receptor for insulin-like growth
factor I in SPARC-null embryonic fibroblasts is also di-
minished [16]. Studies with SPARC-null cells have con-
firmed that SPARC functions in cell proliferation.
Mesangial cells, adult skin fibroblasts and smooth mus-
cle cells from SPARC-null mice proliferate faster than
their respective wild-type counterparts in media con-
taining fetal bovine serum (FBS) [17]. Although embry-
onic fibroblasts from the SPARC-null mice grow at the
same rate as the wild-type cells when they are cultured in
FBS, the SPARC-null embryonic fibroblasts exhibit
down-regulated proliferation as compared to the wild-
type cells when the fibroblasts are cultured in serum-free
medium containing insulin as the sole mitogenic factor
[16]. Thus, it appears that the role of SPARC in cell pro-
liferation is cell type and environment dependent.
Although SPARC is expressed in fibroblasts and macro-
phages at wound sites [18] and functions in many proc-
esses important to wound repair, the role of SPARC in
wound healing in a whole animal has not yet been stud-
ied. Previously, studies of phenotypes in this laboratory
have shown that SPARC-null mice develop osteopenia
around 2.5 months of age [19] in bones where SPARC is
normally the most abundant non-collagenous glycopro-
tein [3]. The second phenotype thus far uncovered is in
the lens where SPARC is normally produced by lens epi-
thelial cells [20,21] and is a component of the lens cap-
sule [20,22]. SPARC-null mice show progressive cataract
formation beginning approximately 1.5 months after
birth [14,21]. Electron microscopy of the SPARC-null
lens revealed abnormality at the lens cell-ECM (capsule)
interface with an intrusion of cellular processes into the
basement membrane of the lens capsule, whereas wild-
type lens exhibited a precise border at the cell-matrix in-
terface [23]. In the present study, we show for the first
time that SPARC plays a role in wound repair in vivo and
in vitro. Wound healing in SPARC-null mice is retarded
due to delayed granulation tissue formation. Repair of a
wound in vitro by dermal fibroblasts is impaired due to
defect in cell migration.
Results
Delayed wound healing in SPARC-deficient mice
Two independent experiments with 25 mm oblong full-
thickness excision wounds (6 mice of each type per ex-
periment), including the striated muscle layer (pannicu-
lus carnosus), on the dorsal skin of wild-type and
SPARC-null mice indicated that the absence of SPARC
impeded healing of skin wounds. One day after surgery a
clear thin film of dried exudate covered the wounds in
the wild-type and SPARC-null mice. Build-up of dehy-
drated wound crusts or scabs began at day 3 and became
subsequently more extensive. In the SPARC-null mice
scabs were thicker and extravasation of blood, visible in
the gaps within the scabs, was more frequent and exten-
sive than that in the control mice. In control wild-type
mice, loss of wound scabs began at day 17 and was com-
plete in all mice by day 24 (Fig. 1A, lower panel) with
wounds well-healed and epithelial covering restored
(Fig. 1A, upper panel). In contrast, the scabs in SPARC-
null mice started to come off partially around day 14, re-
sulting in a scab with a gaping red wound field, which
was evident even at 22 days (Fig. 1A, upper panel). Heal-
ing of SPARC-null wounds remained incomplete on day
24, and complete healing in all mice was observed be-
tween 25 and 31 days (Fig. 1A, lower panel). Similar re-
sults were seen with 30-mm circular excision wounds
(not shown).
Although the larger 25 mm oblong, full thickness exci-
sions allowed us to observe visible differences in woundBMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
healing progression, the wound sites were too fragile to
be isolated for histological examination. We therefore
made 6 mm full thickness circular lesions and examined
the gross and microscopic appearance of skin wounds at
various time points, with four wild-type and four
SPARC-null mice at each time point. Examination of the
gross appearance of wounds showed no apparent differ-
ence in healing progression between wild-type and
SPARC-null mice, with build up of scab at day 1 and loss
of scab by day 10. However, we detected histological dif-
ferences between wild-type and SPARC-null mice. His-
tology of 6 mm wound tissues showed that at day 2 after
wounding the epidermis at wound edges had grown
thicker in both wild-type and SPARC-null mice, indicat-
ing that proliferation of keratinocytes had began. How-
ever, no granulation tissue formation was visible at this
stage of healing in either wild-type or SPARC-null mice
(results not shown). At day 4 reepithelialization and
granulation tissue growth had begun as shown in the 6
mm biopsies in figure 1B. The epidermis had begun to
migrate centrally to cover the wound edge and reepithe-
lialization at this early stage of wound healing in a small
biopsy appeared to be as efficient in SPARC-null mice as
in the wild-type mice except for the more extensive gran-
ulation tissue formation in the wild-type than in the
SPARC-null mice. In wild-type mice, the granulation tis-
sue had formed at the edge and base of the wound. In
SPARC-null mice, the granulation tissue covered the
edge of the wound but did not extend to the base of the
wound (Fig. 1B). At day 6, reepithelialization and granu-
lation tissue formation appeared as elaborate in SPARC-
null mice as in wild-type mice with the neoepidermis and
granulation tissue filling two third of the wound beds
(not shown). By day 10, the wound areas in both control
and mutant mice were smaller, reflecting some degree of
wound contraction, and in addition, the wounds were
now closed, being completely covered by epidermal cells
and underlying granulation tissue (results not shown).
Northern analysis of 6 mm circular wound tissues isolat-
ed during a 6 day healing period showed similar patterns
of cytokeratin 14 expression in SPARC-null mice and
wild-type mice (Fig. 2). Cytokeratin 14 expression is as-
sociated with proliferative epidermal keratinocytes at
wound sites [24]. Such expression in control unwounded
skin (0 day) is, as expected, very low but increased ap-
preciably by day 2 after wounding with peak expression
at day 4. Interestingly, expression of cytokeratin 14 was
up-regulated in the normal epidermis and neoepidermis
of SPARC-null mice relative to those of wild-type mice
(Fig. 2), although histologically no differences in reepi-
thelialization between the SPARC-null and wild-type
wounds were apparent (Fig. 1B). Analysis of α 1(I) colla-
gen and fibronectin transcripts, which are synthesized by
fibroblasts of dermal granulation tissue [25–27], re-
vealed that expression of both transcripts was delayed in
the wounds of SPARC-null mice relative to those of wild-
type mice (Fig. 2). In wild-type mice, both transcripts
were expressed in the unwounded skin (0 day) used as
controls. At day 2, the levels of the two transcripts de-
creased appreciably below the levels of the control skin
followed by an increase in expression between day 2 and
day 4. In the case of SPARC-null mice, expression of the
two transcripts remained below the control unwounded
skin at day 2 and day 4 and did not begin to increase until
between day 4 and day 6 (Fig. 2). Thus, we conclude that
SPARC deficiency compromises granulation tissue for-
Figure 1
Healing of 25 mm oblong skin wounds (A) and histology of 6
mm circular skin wounds (B) in wild-type (+/+) and SPARC-
null (-/-) mice. In (A) upper panel: an example of the progress
of repair processes at the indicated times (days) is shown. S:
scab; W: open wound field. In (A) lower panel: percent of
wild-type and SPARC-null mice (6 in each group) with healed
wounds, defined as loss of the wound scabs and complete
covering of the wounds with epidermis, is plotted versus
days after the excision. Panel (B) illustrates histologic appear-
ance of 6-mm wounds in a wild-type (+/+) mouse and an
SPARC-null (-/-) mouse 4 days after surgery. Granulation (G)
tissue formation is more extensive in the wild-type mouse
than in the SPARC-null mouse. Arrows indicate reepithelial-
ized wound edge. Reepithelialization appears to be as effi-
cient in mutant mice as in control mice. S: scab; P: panniculus
carnosus. Hematoxylin and eosin staining. Scale bar, 210 µm.BMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
mation that involves fibroblast ingrowth and ECM pro-
tein deposition.
Impaired wound repair by cultured SPARC-null fibroblasts
Granulation tissue formation after cutaneous wounding
involves both cell proliferation and migration [1]. How-
ever, these two processes are difficult to analyze in vivo.
To investigate these two processes, a small scrape wound
was made across a confluent monolayer of primary der-
mal fibroblasts and the process of wound closure was
monitored (Fig. 3A). In wild-type cells, at 11 hours after
wounding, repair of the wound was essentially complete
with the denuded area covered with fibroblasts (Fig. 3A,
upper panel). In comparison, repair of the wounded
SPARC-null fibroblast monolayer was retarded (Fig. 3A,
lower panel). The denuded area remained unpopulated
through 11 to 15 hours, even though cells at the edge of
the wound showed forward movement. The first evi-
dence of cell ingrowth did not appear until around 24
hours and wound repair was not complete until some
time between 31 and 48 hours after wounding. Since the
doubling time for these dermal fibroblasts was about 20
hours (our unpublished observation), the healing in
wild-type cells at 11 hours implied that wild-type fibrob-
lasts had extensively migrated from the edge of the
wound into the wound site prior to the onset of cell pro-
liferation. However SPARC-null cells did not show any
migration prior to the onset of cell proliferation and in-
growth was retarded even after the onset of cell prolifer-
ation. This defect in cell motility was rescued to the level
of wild-type cells by the addition of purified SPARC (Fig.
3B). The denuded area was repopulated by the SPARC-
null cells by 11 hours in the presence of added SPARC
(Fig. 3B, lower panel) as compared to 48 hours in its ab-
sence (Fig. 3A, lower panel). The repair of wild-type fi-
broblasts was not affected by the addition of SPARC and
was complete by 11 hours in the presence of exogenous
SPARC (Fig. 3B, upper panel) or in its absence (Fig. 3A,
upper panel). The results indicate that SPARC regulates
wound healing directly through cell migration. Although
the long period of impeded ingrowth of SPARC-null cells
after wounding already suggested defect in cell migra-
tion rather than cell proliferation, we determined cell mi-
gration in the absence of cell proliferation. Mitomycin C
blocks mitosis and thus allows analysis of cell migration Figure 2
Expression of fibronectin, α 1(I) collagen and cytokeratin 14
(ck-14) transcripts (left panel) and levels of mRNA expres-
sion relative to that of GAPDH set at 100 (right panel) in
wounds of wild-type (+/+) and SPARC-null (-/-) mice. Five 6
mm diameter wounds were made on the back of each
mouse. Biopsies were collected from 3 wild-type and 3
SPARC-null mice 2, 4, and 6 days after the surgery. Skin from
the backs of 2 unwounded wild-type and mutant mice (0 day)
was collected and used as controls.
Figure 3
Phase-contrast photomicrographs showing the process of
wound repair by wild-type (upper panel) and SPARC-null
(lower panel) fibroblasts cultured in the absence of SPARC
(A) and in the presence of SPARC (B). In (A), wild-type
(upper panel) and SPARC-null (lower panel) fibroblasts were
grown to confluence in DMEM containing 10% FBS and then
wounded (example shown at 0 hour). Wound closure was
monitored at various time points. Wound healing is delayed
in SPARC deficient fibroblasts. In (B), wounded monolayers
of wild-type (upper panel) and SPARC-null (lower panel)
fibroblasts were cultured in DMEM containing 10% FBS and
SPARC protein purified from human platelets. Exogenous
SPARC restores wound healing ability of SPARC-null cells to
the level of wild-type cells. Scale bar, 62.5 µm.BMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
in the absence of cell proliferation. Treatment with mito-
mycin C did not affect the time course of wound closure
of either the wild-type or SPARC-null cells (Fig. 4). The
wound in a monolayer of wild-type fibroblasts cultured
in the absence or presence of mitomycin C healed by 15
hours after wounding (Fig. 4A). The wound in a monol-
ayer of SPARC-null fibroblasts, whether cultured in the
presence of mitomycin C or in its absence, remained un-
repaired at 15 hours, began to show slight closure at 24
hours and healed by 48 hours (Fig. 4B). These results
confirm that cell migration is a key step affecting the rate
of wound healing and that this process is impaired in
SPARC-null cells. To further test our conclusion, we in-
vestigated whether cell proliferation was affected by the
lack of SPARC. We found that SPARC-null fibroblasts in-
corporated 3H-thymidine as efficiently as control wild-
type fibroblasts over the 25 hour period studied (Fig. 5).
These results together show that indeed cell motility,
rather than cell proliferation, is the major factor in the
retarded wound repair process in SPARC-null cells.
Collagen-gel contraction by SPARC-null fibroblasts is not 
compromised
An important event during wound healing is the contrac-
tion of newly formed granulation tissue by fibroblasts to
bring together the edges of the wound [1]. It has been re-
ported [28] that fibroblasts incorporated in a collagen
gel induce progressive contraction of the gel, resulting in
the formation of a dense collagen disc of greatly reduced
diameter. This phenomenon has been considered as an
in vitro equivalent of the connective-tissue contraction
that occurs during wound healing. We used this proce-
dure to examine the contractile ability of SPARC-null fi-
broblasts. Gel diameter was measured at various time
points following incorporation of fibroblasts in the colla-
gen gel, and the area calculated and expressed as a per-
centage of the initial area. Primary dermal fibroblasts
from SPARC-null mice contracted type I collagen gels as
efficiently as primary dermal fibroblasts from wild-type
mice, contracting to 30% of the initial area at 20 hours
and to 15% by 40 hours after incubation of the fibroblasts
in collagen gels (Fig. 6).
Discussion
In this study, we have shown for the first time that repair
of excision wounds in SPARC-null mice is impaired. His-
tological examination and study of the expression pat-
terns of ECM components, fibronectin and type I
collagen, at the wound site suggested that retarded gran-
ulation tissue formation caused impaired wound repair.
In vitro studies with dermal fibroblasts isolated from
SPARC-null mice further showed that the ability of the
cells to restore wounded areas was hindered and that a
defect in cell migration, rather than cell proliferation,
was the major cause of the delay in repopulating the de-
nuded area. The delayed cell migration and restoration
of the wound site were growth factor independent as
these defects occurred in the presence of FBS. Further-
more these defects were reversed by the addition of puri-
fied SPARC, showing that the defect in cell migration and
wound healing was attributable to the absence of SPARC.
The mechanism by which SPARC influences cell migra-
tion is not known. One possibility is that the lack of
SPARC causes alteration in ECM with respect to struc-
ture and/or function and thus contributes to a decrease
in cell migration. Although SPARC has been postulated
to be involved in wound healing due to its elevated ex-
pression in fibroblasts and macrophages at wound sites
[18], our results are the first to demonstrate that SPARC
indeed plays a role in wound repair and that it does so by
promoting granulation tissue formation through modu-
lation of fibroblast migration.
In large wounds (25 mm), visual examination of wounds
showed that loss of wound scabs and restoration of epi-
dermal covering were delayed in SPARC-null mice due to
premature, partial loss of scabs and neoepidermis, re-
sulting in repeated setbacks in the reepithelialization
process. However, similar setbacks in reepithelialliza-
Figure 4
Wound repair by wild-type (A) and SPARC-null fibroblasts
(B) cultured in the absence (upper panel) or presence (lower
panel) of mitomycin C. Wounded monolayers of wild-type
(A) and SPARC-null fibroblasts (B) were cultured in the
absence (upper panel) or presence (lower panel) of mitomy-
cin C and monitored for wound closure. Wound repair is
not affected by the presence of mitomycin C, an inhibitor of
cell mitosis. Scale bar, 62.5 µm.BMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
tion were not observed in small wounds (6 mm). Fur-
thermore, histological examination of new epidermal
cells in the wound bed and Northern analysis of expres-
sion of a wound keratinocyte marker, cytokeratin 14, in
the biopsied tissues revealed that reepithelialization in
SPARC-null mice was probably not compromised. It
seems possible that reepithelialization occurs normally
in SPARC-null mice. However, since SPARC is a matri-
cellular protein involved in cell-matrix interaction
[3,4,23], cell-matrix interaction-related defects may ex-
ert a significant influence in large wounds of SPARC-null
mice causing premature loss of a part of the scabs and of
the neoepidermis, a pathophysiological process requir-
ing repeated healing. In small wounds, the pathophysio-
logical process caused by the cell-matrix interaction-
related defects may be too small to affect reepithelializa-
tion significantly with the result that restoration of epi-
dermal covering progresses as normally as in the wild-
type mice. Perhaps this size-dependent wound closure
may have contributed to the enhanced wound healing in
SPARC-null mice cited recently as an unpublished result
[29].
Although SPARC is required for migration of dermal fi-
broblasts into the wound site, it is apparently not essen-
tial to the motility of keratinocytes since reepithelializa-
tion appears normal in SPARC-null mice. Thus, the role
of SPARC in cell migration may be cell type-specific,
which has been shown to be the case with in vitro studies
[7,9,10]. Cell motility is controlled by a cycle of cell at-
tachment and detachment. It is generally accepted that
the driving force for cell movement is provided by the dy-
namic reorganization of the actin cytoskeleton, directing
protrusion (lamellipodia and filopodia) at the front of the
cell and retraction at the rear [30,31]. Although we have
not examined the ultrastructure of the dermal fibroblasts
at the edge of wound sites, we showed previously by elec-
tron microscopy that in the lens of SPARC-null mice nu-
merous cellular processes extended into the ECM of the
lens capsule [23]. We further showed that, in contrast to
the abnormal filopodial projections at the lens cell-ECM
interface, cell-cell contacts between the neighboring lens
epithelial cells and between the lens epithelial and fiber
cells were normal [23]. The results indicate that disas-
sembly of cell-cell contacts between lens cells is not tak-
ing place, despite the forward movement of the lens cells
into the ECM of the capsule. In this study, the lack of in-
growth despite the forward movement of cells at the edge
of wounded monolayers suggests that a similar failure of
SPARC-null dermal fibroblasts to break away from its
neighboring cells may account for the impaired cell mo-
tility observed during wound healing in vitro. Previously,
Figure 5
Incorporation of 3H-thymidine by wild-type (+/+) and
SPARC-null (-/-) dermal fibroblasts. Cells were plated and
cultured overnight in DMEM containing 10% FBS. Cells were
then washed with DMEM without FBS and incubated with
3H-thymidine in DMEM containing 10% FBS. Data were
derived from two independent experiments each performed
in triplicate. Bars show mean ± SD.
Figure 6
Contraction of collagen gels by wild-type (+/+) and SPARC-
null (-/-) fibroblasts. Cells were incorporated in collagen gels
and incubated in DMEM plus 2% FBS. Data represent the
average of three independent experiments, each performed
in triplicate.BMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
SPARC has been shown to regulate cell-cell contact
through tyrosine phosphorylation of adherens junction
proteins [32]. Electron microscopy of the SPARC-null
dermal fibroblasts at wound sites should not only con-
firm the role of SPARC in cell motility but also reveal how
SPARC mediates cell-ECM and cell-cell interactions to
promote cell motility.
We showed in the present study that there are no overt
differences in cell proliferation and type I collagen gel
contraction between control and SPARC-null dermal fi-
broblasts. Wound contraction depends on migration of
fibroblasts into the wound site where they lay down their
own collagen-rich matrix [2]. Northern analysis of
wound biopsies showed that production of type I colla-
gen and fibronectin by the null mice, at the beginning of
wound healing, was lower than that by the wild-type
mice. Subsequently, the wound in the null mice was fully
invaded by fibroblasts and expression of type I collagen
and fibronectin by the SPARC-null mice was as abundant
as that by the wild-type mice. Wound contraction takes
place when a wound site is filled with fibroblasts and
ECM [2]. Thus, it is likely that consistent with the in vitro
study wound contraction in the SPARC-null mice is not
compromised.
Conclusions
The delay in granulation tissue formation and healing of
excision wounds in SPARC-null mice, and the defect in
wound closure in in vitro assays indicate that SPARC
plays a role in wound healing through its effect on cell
migration. Cell migration is crucial not only to wound
healing but also to a wide variety of normal or abnormal
biological phenomena such as embryogenesis, leukocyte
immigration into areas of insult, and tumor cell invasion.
SPARC-null mice and their cells should provide a useful
system to investigate how a matricellular protein regu-
lates pleiotropic functions through cell migration and
how its absence alters biological processes.
Materials and Methods
Animals
SPARC-null mice and control wild-type mice used in this
study were generated and maintained on a mixed genetic
background (F2) of 129SvEv ×  C57BL/6j as described
previously [14].
Wound healing assays
Two- to 3-month-old male mice were anesthetized intra-
peritoneally with avertin (0.5 g/kg body weight). The
hair on the back was cut and full-thickness 25 mm ob-
long or 30 mm circular wounds, including panniculus
carnosus, were made. Wounds were neither dressed nor
sutured. Mice were caged individually and progression of
wound repair was monitored daily.
Histology
Five full-thickness 6 mm circular wounds were made on
the back of an anesthetized mouse by a procedure similar
to that described above. The 6 mm diameter wounds pro-
vided stable wound beds appropriate for collection of
wound tissues for histological analysis. Mice were sacri-
ficed by CO2 asphyxia 2, 4, 6, and 10 days after wound-
ing. An area 7 to 8 mm in diameter, which included the
uninjured epithelial margins, was removed, bisected in
the midtransversal plane, fixed in 10% formalin (Buff-
ered Formalde-Fresh, Fisher Scientific, Fair Lawn, NJ)
and embedded in paraffin. Sections (6 µm) were cut from
both faces of bisected tissues and stained with hematox-
ylin and eosin.
RNA analysis
Circular, full-thickness dorsal cutaneous biopsies of 6
mm diameter were made on the backs of anesthetized
mice and wound sites, including the uninjured epithelial
margins, were excised 2, 4, and 6 days post wounding as
described above. Control, unwounded dorsal skin (0
day) was also isolated. The harvested tissues were frozen
immediately in liquid nitrogen. Total RNA was isolated
using guanidine thiocyanate extraction and 15 µg of the
total RNA was analyzed by Northern hybridization as de-
scribed previously [16]. cDNA probes used in hybridiza-
tion were human fibronectin [33], α 1(I) collagen [34], or
cytokeratin 14 cDNA (Hung Tseng, unpublished results).
The same Northern hybridization filters were reprobed
with glyceraldehyde-3-phosphate dehydrogenase (GAP-
DH) cDNA. The amounts of transcripts were quantified
by PhosphoImager (Molecular Dynamics) and normal-
ized to GAPDH transcript. Two independent experi-
ments gave similar hybridization patterns.
Isolation of primary dermal fibroblasts
Primary dermal fibroblasts were prepared from 3 day old
newborn mice. Mice were euthanized by cervical disloca-
tion and sterilized with 70% ethanol. Skin was removed,
washed with phosphate buffered saline (PBS), and incu-
bated overnight in 0.25% trypsin in PBS at 4°C. The der-
mis was separated from the epidermis and subjected to
further incubation overnight in 200 U/ml of crude colla-
genase (Sigma, St. Louis, MO) in Dulbecco's modified
Eagle's medium (DMEM) (Life Technologies Inc., Gaith-
ersburg, MD) at 37°C. Small cell aggregates were sepa-
rated from large tissue fragments by gravitation
sedimentation for 10 minutes at room temperature. The
supernatant was carefully removed, and cells were col-
lected by centrifugation and plated in DMEM containing
10% FBS (Hyclone, Logan, UT) for 48 hours. The cells
were then re-plated twice to deplete from the culture the
residual keratinocytes that do not survive re-plating in
10% FBS-DMEM. The fibroblasts were checked for their
spindle shaped morphology (passage one) and used forBMC Cell Biology 2001, 2:15 http://www.biomedcentral.com/1471-2121/2/15
future experiments. Twenty fibroblast preparations were
made from 10 wild-type or SPARC-null mice. In all ex-
periments, wild-type and SPARC-null cells at identical
passage numbers (<5) were used.
In vitro wound-healing and cell migration assays
Both wild-type and SPARC-null primary dermal fibrob-
lasts were seeded in 6-well plates (5 ×  105 cells/well), and
grown to confluence overnight in DMEM containing 10%
FBS. Monolayers were wounded using a 1 ml plastic mi-
cropipette tip and incubated at 37°C in DMEM contain-
ing 10% FBS or in DMEM containing 10% FBS and
SPARC protein purified from human platelets (48 µg/
ml; Calbiochem, La Jolla, CA). At various time points,
cells were rinsed with PBS and visualized for migration
of cells into denuded space by a phase-contrast micro-
scope. The assays were performed in triplicate in two
separate experiments. To investigate cell motility, mon-
olayers of dermal fibroblasts were prepared and wound-
ed as described above. The wounded monolayers were
incubated at 37°C in DMEM containing 10% FBS with or
without mitomycin C (10 µg/ml, Sigma, St Louis, MO) to
block mitosis. Migration of cells into denuded areas was
monitored for up to 48 hours.
Incorporation of 3H-thymidine
Wild-type and SPARC-null dermal fibroblasts were plat-
ed in 96-well plates (1 ×  104 cells/well) and cultured
overnight in DMEM containing 10% FBS. The cells were
then washed three times with DMEM without FBS and
incubated with 3H-thymidine (1 µCi/ml; NEN, Boston,
MA) in DMEM containing 10% FBS for time periods var-
ying between 0 and 30 hours. Due to the problem of cell
death (>80%) in serum-free medium, cell cycle synchro-
nization of the dermal fibroblasts in serum-free medium
was not performed prior to 3H-thymidine assays. DNA-
bound 3H-thymidine was immobilized on glass fiber fil-
ter paper (Packard, Meriden, CT) with the aid of an auto-
mated cell harvester (Tomtec, Orange, CT) and the
tritium incorporation was determined by scintillation
counting. Experiments were performed in triplicate with
cells derived from two different dermal fibroblast prepa-
rations.
Collagen gel contraction assay
A standard procedure [11] for collagen disc contraction
was followed with minor modifications. Briefly, 6-well
tissue culture plates were made non-adhesive with a
coating of 1% agarose (Sea-Kem LE, FMC BioProducts,
Rockland, MD). One volume of a solution of 3 mg/ml bo-
vine type I collagen (Vitrogen™, Celtrix Corp., Palo Alto,
CA) was combined with 1/6 volume of 7X DMEM and
sufficient 1X DMEM added to yield a final collagen con-
centration of 0.75 mg/ml. A suspension of mouse dermal
fibroblasts at 2 ×  106 cell/ml in DMEM was added to 9
volumes of the type 1 collagen solution, and FBS added to
provide a concentration of 2% FBS in the final solution.
The resulting cell suspension was dispensed into agar-
ose-coated wells (2 ml/well) and gelled for 2 hours at
37°C. DMEM (2 ml) with 2% FBS was subsequently add-
ed to the wells and the gels were gently detached from the
walls to float the collagen disks. The collagen/cell mix-
tures were incubated in humidified air at 37°C and con-
traction was monitored for 72 hours. The assay was
performed three times, each in triplicate. The area of gels
was calculated from the average diameter of the experi-
ments and expressed as a percentage of the initial area.
Abbreviations
DMEM, Dulbecco's modified Eagle's medium; ECM, ex-
tracellular matrix; FBS, fetal bovine serum; GAPDH:
glyceraldehyde-3-phosphate dehydrogenase; PBS, phos-
phate buffered saline; SPARC, secreted protein acidic
and rich in cysteine, also known as osteonectin and BM-
40; SD, standard deviation.
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